View Author
patient cancer 0.00 group -01 breast treatment hsa-mir study tumor trastuzumab docetaxel mirna 0.01 chemotherapy sample therapy breast cancer response expression h ¡d group metastatic vaccination h ϩd group cluster -02 table level progression toxicity metastatic breast cancer fluenza disease analysis transcript month research combination signi trial control signi ficantly group b patient group netherland tumor cells breast cancer patients value april cancer research -03 sequential phase virus survival number association disease progression blood vaccine 5 ctcs profile leukocyte assay difference cycle 1.0 fluenza vaccination 0.02 downloaded ficacy cellsearch method 0.05 single-agent trastuzumab tissue -04 reference 1.00 preamplification
4 Most Recent Publications
|
Response to influenza virus vaccination during chemotherapy in patients with breast cancer
(Article)
Meerveld-Eggink, A. de Weerdt, O. Rijkers, G.T. Biesma, D.H. Velden, A.M.T. van der Los, M. Stouthard, J.M.L. Nijziel, M.R. Westerman, M. Beeker, A. Beek, R.H.T. van Rimmelzwaan, G.F. |
2011-09-01
|
|
Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel
(Article)
Schröder, C.P. Munck, L. de Vader, W. Willemse, P.H. Westermann, A.M. Smit, W.M. Creemers, G.J.M. Graaf, H. de Stouthard, J.M.L. Deijk, G.A. van Erjavec, Z. Bochove, A. van |
2011-06-01
|
|
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients
(Article)
Sieuwerts, A.M. Mostert, B. Kraan, J. Spoel, P. van der Ramírez-Moreno, R. Deurzen, C.H.M. van Smid, M. Yu, J.X. Jiang, J. Wang, Y. Gratama, J-W. Sleijfer, S. Bolt-de Vries, J. Foekens, J.A. Martens, J.W.M. Peeters, D. Jongh, F.E. de Stouthard, J.M.L. Dirix, L. Dam, P.A. van Galen, A. van Weerd, V. de |
2011-06-01
|
|
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: Hertax trial
(Article)
Hamberg, P. Bos, M.M.E.M. Pruijt, J.F.M. Loosveld, O.J.L. Smit, W.M. Muller, E.W. Schmitz, P.I.M. Seynaeve, C.M. Klijn, J.G.M. Braun, H.J.J. Stouthard, J.M.L. Deijk, G.A. van Erdkamp, F.L.G. Stelt-Frissen, I.N. van der Bontenbal, M. Creemers, G.J.M. Portielje, J.E.A. |
2011-04-01
|
